Market Signal Briefing

HBAR Foundation just expanded Hedera's staking reward vault with a $42 million deposit: will the price react accordingly?

Bitcoin price struggled to establish a stable direction in the past week, as intense levels of volatility continue to rock the market. Following two weeks of market correction, the premier cryptocurrency attempted a price rebound, reaching around $112,000 before retracing to $107,000 price zone. 

Presently, Bitcoin trades in the $111,000 price range after some steady gains in the past 48 hours. Interestingly, a popular analyst with the X username DaanCrypto has identified an insightful trend amidst this market uncertainty.

Sideways Bitcoin Market Sets Stage For Explosive Move As Liquidity Builds
In a post on Friday, DaanCrypto shared an important on-chain development of the Bitcoin market following the highly volatile price moves in October 2025.  Despite the consistent price swings, the analyst explains that BTC has remained locked in a local price range over the past two weeks,  with its present price hovering above the midpoint of this structure.

This sideways action has been driven by buyers and sellers repeatedly foiling each other’s attempts to break out, thereby preventing the asset from establishing a decisive breakout pattern. Amid the continuous consolidation, untriggered liquidation levels are accumulating just above and below the local price range.

Source: @DaanCrypto on X
This pattern is typical of Bitcoin’s pre-breakout phases. DaanCrypto explains that the longer the price consolidates within a tight corridor, the more liquidity pools build up outside it. Notably, when price eventually sweeps these clusters, it often triggers a cascade of liquidations and stop orders, which fuel the next large price move. 

Using data from Coinglass, DaanCrypto has identified $106,000 as a level with the heaviest concentration of long liquidations. Therefore, this price point functions as a critical support zone, and a downward wick below which could trigger selling forces pushing Bitcoin to deeper levels. 

Meanwhile, the $115,000 region holds a thick short-side liquidity, meaning a push above this threshold could fuel a rapid short squeeze and propel BTC to higher levels, perhaps beyond its current all-time high at $126,210.

Bitcoin Still On For A Comeback? 
In contrast to popular sentiments of an “Uptober” and blooming Q4, Bitcoin has failed to achieve a sustainable price growth in October. A report from the Bitcoin Archive states that the crypto asset’s return in Q4 2025 is now estimated at -2.84%. This figure shows an extreme underperformance as Bitcoin’s average Q4 is valued at 74.77%.  

However, with over 60 days remaining until the end of 2025, there is still ample time for the premier cryptocurrency to pull off a market recovery. After the CPI data met expectations, the chances of an interest rate cut have increased, and an eventual announcement by the Federal Reserve could perhaps trigger Bitcoin’s rebound, among other factors.

At press time, Bitcoin continues to trade at $111,424, reflecting a 3.91% gain in the past seven days.

BTC trading at $111,493 on the daily chart | Source: BTCUSDT chart on Tradingview.com
 Featured image from iStock, chart from Tradingview

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ACR25--BMS Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR.

Late-breaking positive Phase III data from ianalumab NEPTUNUS-1 and NEPTUNUS-2 trials in Sjögren’s disease to be presented Biomarker data informing use of investigational CAR-T cell therapy rapcabtagene autoleucel (YTB323) in systemic lupus erythematosus also to be presentedData underscore Novartis commitment to advance innovative medicines for complex, difficult-to-treat autoimmune diseases with high unmet needNovartis to hold virtual investor event following ACR highlighting immunology pipeline progress Basel, October 25, 2025 – Novartis announced today plans to present data from 27 company- or investigator-sponsored abstracts across its Immunology portfolio and pipeline at the 2025 American College of Rheumatology (ACR) Convergence. Data to be presented include late-breaking pivotal Phase III results from the replicate NEPTUNUS-1 and NEPTUNUS-2 trials evaluating ianalumab in Sjögren’s disease1. New biomarker data from an ongoing Phase 1/2 study of rapcabtagene autoleucel in severe refractory systemic lupus erythematosus will also be presented, along with Cosentyx data in multiple rheumatology indications2,3.

“Our data at this year’s ACR demonstrate that Novartis is at the forefront of scientific innovation and is developing medicines for some of the most challenging autoimmune diseases, such as Sjögren’s,” said Angelika Jahreis, Global Head, Development, Immunology, Novartis. “Autoimmune diseases are often devastating and life-limiting. We are committed to developing new therapies with the potential to transform the standard of care for the millions who continue to suffer from rheumatic diseases.”

Ianalumab is an investigational medicine that has the potential to become the first targeted therapy for Sjögren’s disease, an area of high unmet need with no FDA-approved treatments4,5. Sjögren’s disease affects millions of people globally and is the second most prevalent rheumatic disease6.

Additional presentations include data for rapcabtagene autoleucel, a novel one-time investigational CAR-T cell therapy being evaluated across several refractory autoimmune disease for its potential to induce an immune reset7-9. Further presentations will feature real-world data on Cosentyx® (secukinumab) in psoriatic arthritis, and new insights into the dual mode of action of ianalumab.

Investor call on Novartis Immunology pipeline 
Following the conclusion of ACR, Novartis will host a conference call for investors to provide updates on the company’s Immunology pipeline on Thursday, October 30, 2025, at 11:30 a.m. ET. Details can be found here.

Key abstracts accepted by ACR include:

Molecule/disease state Abstract title Abstract number/ presentation details      Ianalumab Sjögren’s disease Ianalumab demonstrates significant reduction in disease activity in patients with Sjögren’s Disease: Efficacy and safety results from two global Phase 3, randomized, placebo-controlled double-blind studies (NEPTUNUS-1 and NEPTUNUS-2)  Abstract #LB24
Oral presentation
Oct. 29, 9:15 am – 9:30 am CST Sjögren’s disease Evaluation of the dual mode of action of Ianalumab (VAY736) in the circulation and salivary gland tissue of patients with Sjögren’s Disease: Results from a Phase 2 mechanistic study Abstract #2296
Poster presentation
Oct. 28, 10:30 am – 12:30 pm CST Sjögren’s disease Ianalumab’s dual mode of action: targeting B cells through enhanced B cell depletion and blockade of B cell activating factor receptor signaling Abstract #0903
Poster presentation
Oct. 27, 10:30 am – 12:30 pm CST Systemic lupus erythematosus Achieving sustained lupus low disease activity state and remission with ianalumab (VAY736) in patients with systemic lupus erythematosus: A post hoc analysis from a phase II study Abstract #0801
Oral presentation
Oct. 26, 1:00 pm – 1:15pm CST Rapcabtagene autoleucel Systemic lupus erythematosus Biomarker data from an open-label, Phase 1/2 Study for YTB323 (Rapcabtagene Autoleucel, a rapidly manufactured CD19 CAR-T therapy) suggest reset of the B Cell compartment in severe refractory SLE Abstract #2696
Oral Presentation
Oct. 29, 12:15pm – 12:30 pm CST Cosentyx (secukinumab) Psoriatic arthritis Comparison of incidence of psoriatic arthritis in patients with psoriasis treated with interleukin-17 inhibitors vs interleukin-23 inhibitors, interleukin-12/23 inhibitors, and tumor necrosis factor inhibitors in real-world practice: a retrospective study  Abstract #2689
Oct. 29, 12:15pm – 12:30 pm CST About Novartis Immunology 
At Novartis, we’re advancing bold science for autoimmune diseases, where meaningful therapeutic progress has long stalled.

With a growing legacy of first-in-class innovation across Rheumatology, Dermatology and Allergy, and a diverse industry-leading pipeline, we’re committed to shaping what’s next in Immunology. From small molecules to biologics and CAR-T cell therapy, our innovation is powered by cutting-edge science, focused on where we can have the greatest impact on patient outcomes and supported by strong collaboration across the healthcare ecosystem.

We’re not just treating autoimmune diseases. We’re reimagining medicine, together.

Product information
For full prescribing information, including approved indications and important safety information about marketed products, please visit https://www.novartis.com/about/products

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis 
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.

References

Novartis. Data on file.Morand E, et al. Biomarker Data From an Open-Label, Phase 1/2 Study for YTB323 (Rapcabtagene Autoleucel, a Rapidly Manufactured CD19 CAR-T Therapy) Suggest Reset of the B Cell Compartment in Severe Refractory SLE. Abstract presented at ACR Convergence 2025. Accessed September 19, 2025. https://acrabstracts.org/abstract/biomarker-data-from-an-open-label-phase-1-2-study-for-ytb323-rapcabtagene-autoleucel-a-rapidly-manufactured-cd19-car-t-therapy-suggest-reset-of-the-b-cell-compartment-in-severe-refractory-sle/Armstrong A, et al. Comparison of Incidence of Psoriatic Arthritis in Patients With Psoriasis Treated With Interleukin-17 Inhibitors vs Interleukin-23 Inhibitors, Interleukin-12/23 Inhibitors, and Tumor Necrosis Factor Inhibitors in Real-World Practice: A Retrospective Study. Abstract presented at ACR Convergence 2025. Accessed September 19, 2025. https://acrabstracts.org/abstract/comparison-of-incidence-of-psoriatic-arthritis-in-patients-with-psoriasis-treated-with-interleukin-17-inhibitors-vs-interleukin-23-inhibitors-interleukin-12-23-inhibitors-and-tumor-necrosis-factor-i/Dorner T, et al. Safety and Efficacy of ianalumab in patients with Sjogren’s disease: 52-week results from a randomized, placebo-controlled, phase 2b dose-ranging study. Arthritis and Rheumatology. 2025; 77(5):560-570 Negrini S, et al. Sjogren’s syndrome: a systemic autoimmune disease, Clin Exp Med. 2022; 22(1): 9-25 National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Care Services; Committee on Selected Immune Disorders and Disability. Sjogren’s Disease/Syndrome. Accessed September 11, 2025. https://www.ncbi.nlm.nih.gov/books/NBK584486/  ClinicalTrials.gov NCT05798117 [Last accessed: September 2025] ClinicalTrials.gov NCT06665256 [Last accessed: September 2025] ClinicalTrials.gov NCT06655896 [Last accessed: September 2025] # # #

October 25, 2025 11:01 ET

 | Source:

Cullinan Therapeutics, Inc.

CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases

CAMBRIDGE, Mass., Oct. 25, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, will present new preclinical data for CLN-978, its novel investigational CD19xCD3 bispecific T cell engager. These data will be presented at the American College of Rheumatology (ACR) Convergence 2025, being held in Chicago, Illinois, October 24-29, in a poster presentation session on October 28, 10:30 a.m.-12:30 p.m. CT (Poster Session C, Poster Number 2293). Cullinan will also have a Booth (#1074) in the Exhibit Hall.

New in vitro preclinical data show CLN-978 robustly and specifically depleted target B cells while activating T cells in human peripheral blood mononuclear cells (PBMC) derived from patients with rheumatoid arthritis (RA), Sjögren's disease (SjD), or systemic lupus erythematosus (SLE). These effects were similar to those observed with PBMCs from healthy donors.

Dose-dependent B cell depletion was observed following subcutaneous administration of CLN-978 in nonhuman primates (NHPs). Doses of CLN-978 considered well tolerated in the NHPs achieved deep and sustained B cell depletion in blood and multiple tissues including bone marrow and lymph nodes, suggesting the potential to achieve meaningful B cell depletion in patients.

In a murine model of SLE, CLN-978 treatment led to a reduction in circulating B cells, levels of anti-dsDNA IgG, and IgG deposition in the kidney, indicating a disease-modifying effect in both peripheral blood and affected disease tissues.

“We continue to generate preclinical data that reinforce the potential of CLN-978 as a highly potent T cell engager designed to deplete B cells deeply across multiple autoimmune diseases,” said Jeffrey Jones, MD, MBA, Chief Medical Officer, Cullinan Therapeutics. “In parallel, we are advancing our global clinical programs in rheumatoid arthritis, Sjögren’s disease, and systemic lupus erythematosus, recognizing the significant unmet needs for people living with these diseases. Current therapies are typically limited to addressing disease symptoms whereas CLN-978 has the potential to modify the underlying pathophysiology of the disease itself.”

Cullinan is advancing the global clinical development of CLN-978 through its OUTRACE studies across RA (NCT06994143), SjD (NCT07041099), and SLE (NCT06613360), with active trials now underway across all three indications and in multiple countries.

About CLN-978
CLN-978 is a novel, differentiated and highly potent CD19xCD3 bispecific T cell engager. CLN-978 triggers redirected lysis of CD19-expressing target cells in vitro and in vivo. CLN-978 is engineered to achieve very high affinity binding to CD19 to efficiently target B cells, including those with very low CD19 levels. Small in molecular size (65 kDa), CLN-978 contains two single-chain variable fragments, one binding with very high affinity to the CD19 target and the other binding to CD3 on T cells, and a single-domain antibody binding to human serum albumin to extend serum half-life. CLN-978 was developed by an internal Cullinan team and is a wholly owned asset. CLN-978 has the potential to offer a convenient, off-the-shelf, subcutaneously delivered therapeutic option for patients living with autoimmune diseases and is being studied in Cullinan’s OUTRACE studies for patients with rheumatoid arthritis, Sjögren’s disease, and systemic lupus erythematosus. CLN-978 is investigational and has not been approved by any health authority.

About Cullinan Therapeutics   
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, high-impact therapies for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow Cullinan on LinkedIn and X. 

Forward Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding the company’s beliefs and expectations regarding: future data presentations, our preclinical and clinical developments plans and timelines for CLN-978, the clinical and therapeutic potential of CLN-978, and other statements that are not historical facts. The words “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “plan,” “potential,” “project,” “pursue,” “will,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: uncertainty regarding the timing and results of regulatory submissions; the risk that any INDs or other global regulatory submissions we may file with the United States Food and Drug Administration or other global regulatory agencies are not cleared on our expected timelines, or at all; the success of our clinical trials and preclinical studies; the risks related to our ability to protect and maintain our intellectual property position; the risks related to manufacturing, supply, and distribution of our product candidates; the risk that any one or more of our product candidates, including those that are co-developed, will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies; and the success of any collaboration, partnership, license or similar agreements. These and other important risks and uncertainties discussed in our filings with the Securities and Exchange Commission, including under the caption “Risk Factors” in our most recent Annual Report on Form 10-K and subsequent filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except to the extent required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Moreover, except as required by law, neither the company nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made.

Contacts:

Investors
Nick Smith
+1 401.241.3516
[email protected]

Media
Rose Weldon
+1 215.801.7644
[email protected]

Pinnacle Silver & Gold Corp (TSX-V:PINN, OTCQB:NRGOF) CEO Robert Archer talked with Proactive about the company’s recent strategic shift, including its new project in Mexico and key personnel hires to support its development.

The project, El Potrero, was acquired at the end of February and marks a renewed focus for the company. Archer explained that the business model reflects his past work at Great Panther, with the objective to rapidly restart past-producing mines and build the company through operational cash flow, rather than relying on equity markets.

Archer described El Potrero as a previously producing asset that was active in the late 1980s, with no modern exploration since the 1990s. “We think there's a lot of potential there,” he said, adding that remnants of an existing plant offer an opportunity for a faster restart.

To advance the project, Pinnacle has brought back two experienced team members: Carlos, who will lead operations, and Jorge, on the exploration side—both of whom worked with Archer at the Guanajuato mine. Archer said, “Carlos has worked for me a couple of times... I think I can honestly say he was the best mine manager that we ever had.”

The next steps include finalising mine planning and assessing the plant rebuild, with more than 1,000 samples already collected over the past eight months.

Netflix Inc (NASDAQ: NFLX) tanked below its 200-day moving average this week – triggering concerns among technical traders. But widely followed investor, Josh Brown, remains constructive on the streamer for the long-term.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of WFC.PR.Z either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

I also have a long position in WFC.PR.L.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

-

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of MidWestOne Financial Group, Inc. (NasdaqGS: MOFG) to Nicolet Bankshares, Inc. (NYSE: NIC). Under the terms of the proposed transaction, shareholders of MidWestOne will receive 2.6 shares of Farmers common stock for each share of MidWestOne that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ([email protected]) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgs-mofg/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

More News From Kahn Swick & Foti, LLC

Back to Newsroom

Intel (INTC) stock pulls back during intraday trading on Friday, erasing initial gains following the legacy chipmaker's earnings report. Bernstein managing director and senior analyst Stacy Rasgon, who lifted his price target on the stock but maintained his market performance rating, explains why Intel shares reversed direction after releasing quarterly results.

Data demonstrate BBO-10203 blocks RAS-mediated activation of PI3Kα and strongly inhibits pAKT signaling in tumor cells without affecting glucose metabolismRobust monotherapy activity, as well as combination activity with BBOT’s KRASG12C ON/OFF inhibitor, BBO-8520, and panKRAS inhibitor, BBO-11818, was observed at well-tolerated dose levels in a panel of KRAS-mutant modelsThe combination of a KRAS inhibitor with a PI3Kα pathway inhibitor may maximize the response rate and reduce the development of adaptive resistance mechanisms due to full inhibition of both MAPK and PI3Kα signalingBBOT-10203 is currently being evaluated in the Phase 1 BREAKER-101 trial for patients with HER2+ amplified or HR+/HER2- breast cancer, and KRAS mutant colorectal or non-small cell lung cancer with initial Phase 1 clinical data expected in the first half of 2026 SOUTH SAN FRANCISCO, Calif., Oct. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced new preclinical data showing BBO-10203 selectively and specifically blocks the physical interaction between RAS and PI3Kα, resulting in the inhibition of RAS-driven PI3Kα-AKT signaling in tumors without the risk of hyperglycemia. In addition, combination activity with BBOT’s KRASG12C ON/OFF inhibitor, BBO-8520, and panKRAS inhibitor, BBO-11818, was observed at well tolerated dose levels in a panel of KRAS mutant models. The data were presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

“Aberrant activation of the PI3Kα pathway is among the most common oncogenic drivers across human cancers and leads to promotion of tumor growth, survival, and resistance to standard therapies,” said Pedro Beltran, PhD, Chief Scientific Officer of BBOT. “Current PI3Kα inhibitors are hindered by dose-limiting toxicities like hyperglycemia, which restrict target coverage, limit the number of eligible patients, and shorten the duration of treatment – leaving a significant unmet medical need. We’ve designed BBO-10203 to break the interaction between RAS and PI3Kα and inhibit RAS-mediated activation of the PI3Kα pathway. These preclinical data demonstrate BBO-10203 can accomplish this in in vivo studies without affecting glucose metabolism and achieve robust anti-tumor activity both as a monotherapy and in combination with our KRAS inhibitors, BBO-8520 and BBO-11818.”

These preclinical findings demonstrate BBO-10203 covalently binds PI3Kα on cysteine 242 in the RAS binding domain, breaking the protein-protein interaction between RAS and PI3Kα. Monotherapy results show achievement of complete cellular target engagement at low nanomolar concentrations and oral bioavailability with robust dose- and time-dependent inhibition of pAKT across diverse human cancer cell lines with KRAS mutations. Importantly, BBO-10203 does not induce hyperglycemia or hyperinsulinemia during an oral glucose tolerance test. In a panel of cell-line derived xenograft (CDX), patient-derived xenograft (PDX), and genetically engineered mouse (GEM) models, treatment with BBO-10203, both as a monotherapy and in combination with BBO-8520, BBOT’s direct inhibitor of KRASG12C in both the ON and OFF states, and with BBO-11818, the company’s panKRAS inhibitor targeting mutant KRAS in both the ON and OFF states with strong potency against KRASG12D and KRASG12V mutants, show robust anti-tumor activity. Importantly, the combination of BBO-10203 + BBO-8520 and BBO-10203 + BBO-11818 induces deep tumor regressions through direct effects on tumor cell proliferation and apoptosis and are well-tolerated.

BBO-10203 is currently being evaluated in the Phase 1 BREAKER-101 trial for patients with HER2+ amplified or HR+/HER2- breast cancer, and KRAS mutant colorectal or non-small cell lung cancer as a monotherapy and in combination with standard of care treatment, and will be evaluated in combination with KRAS inhibitors.

“We are pleased to share these preclinical data on BBO-10203’s potential as a RAS:PI3Kα breaker,” said Eli Wallace, PhD, Chief Executive Officer of BBOT. “By breaking the interaction between RAS and PI3Kα while preserving normal insulin signaling, these results further support our belief that BBO-10203 represents a truly differentiated approach with significant biological and therapeutic potential. We continue to enroll patients in our Phase 1 BREAKER-101 trial and look forward to expanding into combination studies, including with our own KRAS inhibitors.”

A copy of the poster titled “BBO-10203, a first-in-class, orally bioavailable, selective breaker of the RAS:PI3Kα interaction inhibits tumor growth alone and in combination with KRAS inhibitors in KRAS mutant models without inducing hyperglycemia” will be available on the “Publications” page of the BBOT website following the conference.

About BBO-10203
BBO-10203 is a first-in-class small molecule which breaks the protein-protein interaction between RAS and PI3Kα and inhibits RAS-mediated activation of the PI3Kα pathway. It selectively disrupts oncogenic RAS-PI3Kα signaling while sparing insulin-mediated glucose uptake, potentially maintaining efficacy with reduced risk of hyperglycemia or hyperinsulinemia. BBO-10203 is currently being evaluated in the Phase 1 BREAKER-101 trial for patients with locally advanced or metastatic HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer. Initial Phase 1 clinical data are expected in the first half of 2026.

About BBOT
BBOT is a clinical-stage biopharmaceutical company advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Kα malignancies. BBOT has the goal of improving outcomes for patients with cancers driven by the two most prevalent oncogenes in human tumors. For more information, please visit www.bbotx.com and follow us on LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws. Any statements in this press release that are not historical facts may be deemed forward-looking statements,  which generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends. These statements are based on various assumptions, whether or not identified in this press release, and are the current expectations of BBOT’s management and are not predictions of actual performance. Many actual events and circumstances are beyond the control of BBOT. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; risks relating to the uncertainty of the projected financial information with respect to BBOT; risks related to the approval of BBOT’s product candidates and the timing of expected regulatory and business milestones, including the progress of enrollment in clinical trials and availability of data from ongoing and planned clinical trials; the impact of competitive products; risks relating to BBOT’s ability to obtain sufficient supply of materials; and those factors discussed in documents BBOT has filed or will file with the U.S. Securities and Exchange Commission.

In addition, forward-looking statements reflect BBOT’s expectations, plans, or forecasts of future events and views as of the date of this press release and are qualified in their entirety by reference to the cautionary statements herein. BBOT anticipates that subsequent events and developments will cause BBOT’s assessments to change. These forward-looking statements should not be relied upon as any guarantee, assurance, prediction or definitive statement of fact or probability or as representing BBOT’s assessments as of any date subsequent to the date of this press release. Neither BBOT, nor any of its affiliates undertake any obligation to update these forward-looking statements, except as required by law.

BBOT Contacts:

Investor Contact:
Heather Armstrong, Head of Investor Relations
BBOT
[email protected]

Media Contact:
Jake Robison
Inizio Evoke Comms
[email protected]

NEW YORK, Oct. 25, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the “Class Period”), of the important November 18, 2025 lead plaintiff deadline.

SO WHAT: If you purchased Jasper Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Jasper Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=45109 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 18, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Jasper lacked the controls and procedures necessary to ensure that the third-party manufacturers on which it relied were manufacturing products in full accordance with cGMP regulations and otherwise suitable for use in clinical trials; (2) the foregoing failure increased the risk that results of ongoing studies would be confounded, thereby negatively impacting the regulatory and commercial prospects of Jasper’s products, including briquilimab; (3) the foregoing increased the likelihood of disruptive cost-reduction measures; (4) accordingly, Jasper’s business and/or financial prospects, as well as briquilimab’s clinical and/or commercial prospects, were overstated; and (5) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Jasper Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=45109 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        [email protected]
        www.rosenlegal.com

Netflix (NASDAQ: NFLX) shares have entered dangerous technical territory, flashing multiple bearish signals that suggest momentum could unravel further. 

The stock closed at $1,094, slipping below all its major moving averages, the 20-day, 50-day, 100-day, and 200-day, in a sharp move that often precedes extended downside pressure.

Notably, the stock has had a rough couple of sessions, dropping almost 10% in the past week. Still, it remains up 23% year-to-date. 

Netflix stock price analysis chart. Source: Barchart
This marks the first time since the streaming giant’s long-term uptrend began that Netflix has decisively fallen below its 200-day simple moving average (SMA) of $ 1,114.33. The last such breach saw shares trading under $350.

Netflix stock price analysis chart. Source: TrendSpider
Additionally, momentum indicators are flashing warnings. The RSI sits just above oversold levels, signaling accelerating bearish momentum despite signs of short-term exhaustion. 

While similar readings have previously led to brief stabilization, the current setup appears far weaker. 

Rising selling volume near support suggests institutions may be trimming exposure after months of consolidation. With Netflix now trading below all major trendlines, bulls must quickly reclaim the 200-day moving average or risk a deeper correction.

Why Netflix is falling 
The latest bearish sentiment toward Netflix comes despite upbeat revenue and earnings guidance, as investors focused on a weaker-than-expected operating margin and renewed valuation concerns. 

In the most recent quarter, the streaming entity posted a 28% operating margin, below its 31.5% forecast, due to an unexpected tax expense in Brazil. Although Netflix said the issue won’t affect future results, it trimmed its 2025 margin outlook to 29% from 30%.

At the same time, the stock has faced uncertainty amid rising competition from AI-driven content platforms and renewed backlash after Elon Musk urged users to cancel subscriptions over “woke” content. 

Despite strong ad sales and hit titles, investors remain cautious about Netflix’s profitability and valuation heading into 2025.

Featured image via Shutterstock

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Oct 25, 2025 at 14:23 // Price

Sui's price has resumed its decline after rising above the $2.48 support. SUI price analysis by Coinidol.com.

SUI price long-term prediction: bearish

The cryptocurrency has already fallen to a low of $2.00, but the bulls bought the dips. The upward correction was short-lived, ending at a high of $3.01. Yesterday, SUI fell to a low of $2.28 and began moving sideways.

On the downside, if the bears breach the $2.30 support level, SUI will revert to its previous low of $2.00. If the current support holds, SUI will be forced to trade in a range above $2.30. SUI may then rise and retest the $3.00 barrier. At the time of writing, SUI is trading at $2.49.

Technical indicators

Key supply zones: $4.00, $4.20,$4.40

Key demand zones: $3.00, $2.80, $2.60 

SUI price indicator analysis

The moving average lines are trending downward, and the 21-day SMA is below the 50-day SMA, indicating a downtrend. On the 4-hour chart, the moving average lines are horizontal, indicating a sideways trend. Doji candlesticks dominate the price action, keeping the altcoin in a range.

SUI/USD daily chart - September 24, 2025

What is the next move for Sui?

SUI continues to move sideways, above the $2.30 support but below the $3.00 resistance. The moving average lines have impeded the price's upward movement. The cryptocurrency price remains locked below the moving average lines. Doji candlesticks dominate the altcoin market, signalling that traders are uncertain about its direction.

SUI/USD 4-hour chart - September 24, 2025

Disclaimer. This analysis and forecast are the personal opinions of the author. The data provided is collected by the author and is not sponsored by any company or token developer. This is not a recommendation to buy or sell cryptocurrency and should not be viewed as an endorsement by Coinidol.com. Readers should do their research before investing in funds. 

Ethereum’s rebound setup strengthens as whale wallets add roughly $588 million in ETH over 24 hours.Dormant coin movement falls 88%, hinting that holders are staying put and conviction is growing.Key resistance levels at $3,986 and $4,281 remain crucial for confirming a full Ethereum price reversal and sustained rally.Ethereum (ETH) is once again teasing a turnaround. Over the past month, the Ethereum price has slipped about 1.9%, but the past seven days show a mild 2.1% rebound, as traders attempt to recover lost ground.

Still, the broader tone remains slightly negative. Previous bounces failed to extend into full rallies, repeatedly capped at key technical levels. Now, with on-chain data shifting again, another rebound is forming — and this one looks more convincing.

Sponsored

Whales Add While Dormant Holders RiseThe Spent Coins Age Band, a metric that tracks how much ETH moves across wallets of all ages, has dropped from 346,000 ETH on October 22 to just 42,100 ETH on October 25 — an 88% decline in movement.

That means coins are staying put rather than circulating — a strong signal that dormant holdings are rising and holders are showing renewed conviction. Both short and long-term investors appear to be waiting for higher prices before rotating their assets.

Fewer ETH Moving: SantimentWant more token insights like this? Sign up for Editor Harsh Notariya’s Daily Crypto Newsletter here.

Spent Coins Age Band shows total ETH moved across age bands. When it drops, fewer coins are leaving wallets, signaling higher dormancy — often a bullish sign.

Sponsored

At the same time, whale addresses holding more than 10,000 ETH have increased their combined holdings. Over the past 24 hours, they have raised their stash from 100.41 million to 100.56 million ETH. That’s a net gain of 150,000 ETH, worth around $588 million at current ETH prices.

Ethereum Whales Back To Buying: SantimentThis mix of rising dormancy and fresh whale accumulation creates a stronger base for Ethereum. Historically, when large holders buy while fewer coins move on-chain, the price tends to stabilize and prepare for the next major leg upward.

One Indicator Holds Ethereum’s Reversal Theory IntactThe Relative Strength Index (RSI) — an indicator that measures the balance between buying and selling pressure — continues to flash signs that Ethereum’s downtrend may be losing strength.

Sponsored

Between September 25 and October 22, the RSI made higher lows while the price made lower lows, forming a bullish divergence that often signals a potential reversal. Similar divergences appeared on October 10 and October 17, both of which led to short-lived bounces.

Ethereum Reversal Theory Still Intact: TradingViewThis time, however, the supporting on-chain data looks stronger, suggesting the setup could finally evolve into something larger.

Sponsored

Fibonacci Still Defines The Ethereum Price Reversal PathDespite improving technicals, the Ethereum price remains trapped below critical resistance zones that have repeatedly capped every bounce. The 0.382 Fibonacci level at $3,986 and the 0.618 level at $4,281 have rejected two rally attempts in a row — including those on October 10 and October 17.

To confirm real strength, ETH needs a daily close above $4,281, roughly 9% above current levels. That would mark the first clear shift in market control, possibly setting the stage for targets at $4,491 and $4,954.

Ethereum Price Analysis: TradingViewIf the breakout fails and ETH slips below $3,804, a deeper pullback toward $3,509 could follow. For now, though, the setup looks cleaner than before — whale accumulation, rising dormancy, and a well-defined technical ceiling.

Ethereum’s rebound isn’t guaranteed, but this time, the groundwork beneath it looks stronger than ever.

Disclaimer

In line with the Trust Project guidelines, this price analysis article is for informational purposes only and should not be considered financial or investment advice. BeInCrypto is committed to accurate, unbiased reporting, but market conditions are subject to change without notice. Always conduct your own research and consult with a professional before making any financial decisions. Please note that our Terms and Conditions, Privacy Policy, and Disclaimers have been updated.

ETH $10K Path Projected by Analyst as Ether Whales and Sharks Show ‘Signs of Confidence’Analysts on X outlined five-digit targets for ether while Santiment said larger wallets have started adding again, framing a longer path higher if resistance gives way. Oct 25, 2025, 3:02 p.m.

Ether ETH$3,933.85 hovered near $3,946 at 13:57 UTC on Oct. 25 after a high-volume rejection around $4,000 left price coiling below resistance, while analysts outlined five-digit scenarios and on-chain data pointed to larger wallets adding.

Analyst viewAnalyst Ali Martinez projected a long-term path to $10,000, cautioning it may take longer than some expect; his weekly sketch implies a pullback into 2026 followed by a climb toward five digits around 2027–2028.

Separately, The Long Investor set a $13,500 target by 2029, framing a multiyear trajectory rather than a near-term call.

On the flows side, Santiment said “whales and sharks” holding 100–10,000 ETH have added back roughly one-sixth of the coins they sold between Oct. 5 and Oct. 16, describing that as a sign of improving confidence among larger accounts.

Together, the views lean constructive over a multi-year horizon, but they also imply that clearing major resistance levels must come first before momentum can compound.

Session overview According to CoinDesk Research’s technical analysis data model, ether ETH$3,933.85 moved from $3,955.91 to $3,937.05 over the prior 24-hour session ending this morning (UTC), a roughly $120 swing (about 3.1% intraday) that finished near the lower end. The model marks resistance in the $3,945–$4,000 zone and support around $3,870–$3,880, with an immediate shelf near $3,930. The structure reflects a narrowing range beneath a round-number ceiling and above a recently defended support area.

Volume and intraday contextThe key inflection came when volume jumped 188% above the 24-hour average — peaking at 444,887 contracts — during a failed push through the $4,000 level. Price briefly tagged $4,001.69 before sellers capped the move.

After that rejection, ETH made lower peaks and settled into a late-session rectangle between $3,930 and $3,940 as activity cooled. A smaller burst of 23,884 contracts lifted price toward $3,948, but it faded without follow-through above $3,945, reinforcing the idea that $3,945–$4,000 is the local cap that needs a decisive break.

What to watch nextA clean break and hold above $4,000 on UTC closes would open $4,100 and put early-month highs back in view; failing that, a loss of the immediate $3,930 shelf would likely send price to the $3,870–$3,880 demand area identified by the model. The analyst projections are multi-year and do not depend on a single day’s tape, but near-term traction still hinges on converting the high-$3,900s into support.

CoinDesk 5 Index (CD 5)Over the same window, the CoinDesk 5 Index rose from 1,945.13 to 1,953.72 after reversing from an intraday low at 1,922.57 and stalling near 1,961.57, with support firming around 1,920–1,925 after multiple checks.

Latest 24-hour and one-month chart read As of 13:57–13:58 UTC on Oct. 25, ETH was $3,946 (up 0.5% over the period). On the 24-hour chart, the session opened near $3,926, reached a high at $3,957 and a low at $3,876. In practical terms, $3,900–$3,920 acted as intraday buy zones, and $3,950–$3,960 capped rebounds ahead of the next attempt at $4,000.

On the one-month chart, ETH has rebounded from the mid-October dip and is grinding back toward $4,000, still below early-month highs — a setup that supports the analyst view of a longer road higher, provided resistance gives way and reclaimed levels hold on subsequent retests.

Disclaimer: Parts of this article were generated with the assistance from AI tools and reviewed by our editorial team to ensure accuracy and adherence to our standards. For more information, see CoinDesk's full AI Policy.

More For You

Stablecoin payment volumes have grown to $19.4B year-to-date in 2025. OwlTing aims to capture this market by developing payment infrastructure that processes transactions in seconds for fractions of a cent.

View Full Report

More For You

Bitmine’s Tom Lee Sees Crypto Rally Into Year-End, Says S&P 500 Could Climb Another 10%

On CNBC, Tom Lee said Fed cuts and fading skepticism could lift U.S. stocks into year-end and that crypto may rebound as open interest resets and technicals improve.

What to know:

Lee said the S&P 500 could add 4%–10% by year-end 2025, taking it above 7,000, citing Fed cuts and persistent investor skepticism.He called Oct. 10 “the biggest liquidation event in five years” in crypto and said record-low open interest plus improving technicals set up a year-end rallyLee argued bitcoin acted like a store of value during the flush and said Ethereum activity on L1/L2 driven by stablecoins supports a “pretty big move.”Read full story

The feature is developed with Tether and was announced at the Plan ₿ Forum in Lugano, Switzerland. The first BTC tip was sent to content creator David Freiheit.Updated Oct 25, 2025, 3:06 p.m. Published Oct 25, 2025, 3:06 p.m.

Video platform Rumble (RUM) plans to launch bitcoin tipping for its 51 million monthly users by mid-December, expanding how creators can earn directly from their audiences.

The new feature, developed in partnership with Tether, allows viewers to send BTC tips through a digital wallet built into the app. It was announced during the Plan ₿ Forum in Lugano, Switzerland.

The company said it’s still testing the system. The first BTC tip was sent to Canadian content creator David Freiheit.

Loading...

Leading stablecoin issuer Tether has invested $775 million in Rumble and has supported the company. It’s set to leverage the video-sharing platform to push its U.S. compliant stablecoin USAT to 100 million Americans.

Rubmle has also adopted a bitcoin treasury strategy. The firm has so far accumulated 211 BTC, according to Bitcointreasuries data.

More For You

Stablecoin payment volumes have grown to $19.4B year-to-date in 2025. OwlTing aims to capture this market by developing payment infrastructure that processes transactions in seconds for fractions of a cent.

View Full Report

More For You

North Korea’s AI-Powered Hackers Are Redefining Crypto Crime

Mysten Labs’ chief cryptographer warns that artificial intelligence, not quantum computing, poses the real near-term threat to blockchain security.

What to know:

North Korea’s hackers now use advanced AI tools to scan codebases, identify vulnerabilities and replicate successful exploits across multiple blockchains within minutes.With AI handling reconnaissance, phishing and money laundering, small state-backed hacker teams are able to operate with industrial-level efficiency and precision.Experts say AI, not quantum computing, poses the immediate threat, accelerating crypto theft and forcing exchanges to adopt continuous, AI-aware security audits.Read full story

Fetch.ai opens class-action lawsuit after Ocean Protocol allegedly moves 270 million FET to exchanges.

Sat, 25/10/2025 - 15:33

The Shiba Inu Layer-2 blockchain Shibarium saw a sudden 742% surge in its daily transactions, which is sparking speculation regarding a potential comeback.

Cover image via U.Today

Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

Shiba Inu Layer 2 Shibarium suddenly saw a surge in daily transactions, rising as much as 742% in the last 24 hours.

According to Shibariumscan, Shibarium recorded 17,270 in daily transactions in the last 24 hours, a sharp surge from the figure of 2,050 recorded Oct. 22, marking a 742% surge.

Shibarium transactions have largely fluctuated since Sept. 25 in a broad range from 1,970 to 19,620.

HOT Stories

Shibarium no doubt saw large spikes but couldn't exceed 19,620, they were usually followed by a sharp drop, creating a haphazard pattern in the transaction record.

Though it might seem transactions on Shibarium picked up at some point in the month, they still remain far from the millions previously recorded on the Layer-2 blockchain.

Recent data from Shibariumscan gives the current count of total transactions as 1,568,611,766; total addresses as 272,707,592 and total blocks as 13,753,754.

Shiba Inu down 15% in October, but hopes remainShiba Inu is currently down 15% in October, a month marked by forced selling and false starts, with a historic sell-off dampening an otherwise bullish month for cryptocurrencies.

The market is adjusting to a slow grind higher after October’s record liquidation event, which erased nearly $20 billion in open interest and left leveraged traders in losses.

Underneath the surface, sentiment remains mixed. The fear index has hovered at fear for days, indicating that market sentiment remains cautious, with traders awaiting macroeconomic catalysts.

Fundstrat's Tom Lee referred to the Oct. 10 flash crash as the biggest liquidation event in five years in crypto; despite this, Lee predicts that crypto might rally into year-end after a sharp deleveraging, laying out his case during an interview Friday on CNBC’s Closing Bell.

Related articles

Why Trust CoinGape

CoinGape has covered the cryptocurrency industry since 2017, aiming to provide informative insights to our readers. Our journal analysts bring years of experience in market analysis and blockchain technology to ensure factual accuracy and balanced reporting. By following our Editorial Policy, our writers verify every source, fact-check each story, rely on reputable sources, and attribute quotes and media correctly. We also follow a rigorous Review Methodology when evaluating exchanges and tools. From emerging blockchain projects and coin launches to industry events and technical developments, we cover all facets of the digital asset space with unwavering commitment to timely, relevant information.

Bitcoin price is hovering around $111,742, reflecting a 0.5% gain in the last 24 hours. With a 5 % increase over the past week, Bitcoin eyes the $120K mark amid ongoing market consolidation. 

The broader cryptocurrency market saw a modest 0.48% rise, with altcoins like XRP, SOL, ADA, and DOGE  also showing slight gains. Despite the prevailing bearish sentiment, Bitcoin holds strong above key support levels, bolstered by the growing likelihood of a Federal Reserve rate cut.

Bitcoin ETFs have recently experienced a net outflow of $90.60 million, marking three consecutive days of withdrawals. In contrast, Bitcoin itself saw a positive shift, with spot ETFs recording a net inflow of $149.96 billion.

Source: Sososvalue
Fed Rate Cut Expected: 98% Probability Next Week
U.S. consumer inflation in September rose less than anticipated, both on a monthly and annual basis. The data has increased expectations that the Federal Reserve will implement a rate cut next week. 

According to CME’s FedWatch tool, there is now a 98% likelihood of the Fed lowering rates at its next meeting. The latest inflation numbers, along with signs of a slowing labor market, have bolstered market confidence that the central bank may also cut rates again in December. This potential rate cut could boost investor sentiment, potentially driving up demand for riskier assets like Bitcoin.

Analyst Predicts BTC Price Movement Towards $112,000
Bitcoin price has once again rebounded from its crucial $110,000 support zone, displaying resilience in the market. The cryptocurrency’s ability to hold above this level signals potential for further upward movement, but the next significant hurdle lies at the $112,000 mark.

Reclaiming the $112,000 resistance is essential for Bitcoin to initiate a fresh uptrend. This level is pivotal for driving positive momentum and reaching higher price levels. A successful break above this zone could open the path towards $113,000 and beyond.

$BTC bounced back from its $110,000 support zone again.

The next crucial level to reclaim is $112,000 which will start the next uptrend.

If Bitcoin gets rejected again, expect a sharp correction towards the $108,000-$110,000 level. pic.twitter.com/EfJepr27EY

— Ted (@TedPillows) October 25, 2025

However, if Bitcoin faces rejection at this resistance again, it could experience a sharp decline. The primary support zone to watch for a potential correction is between $108,000 and $110,000. A failure to hold this range could lead to further downward pressure.

BTC Price Targets $120K: Bullish Momentum Builds
BTC price has shown a notable recovery recently, moving above the $111,500 mark after experiencing some fluctuations over the past few days. 

Source: BTC/USD 4-hour chart: Tradingview
The Relative Strength Index (RSI) currently stands at 60, indicating that the BTC is in the neutral zone. The Moving Average Convergence Divergence (MACD) also paints a picture of bullishness with the MACD line positioned above the signal line.

If the BTC price forecast continues to hover around $111k, it will likely encounter significant resistance near $120k  and beyond, which could trigger another consolidation phase. On the downside, Bitcoin has strong support at the $105,000 level, where buyers might step in to stabilize the price.

Bonk Holdings Inc. (BNKK) has made its first large purchase of $32 million worth of BONK. The purchase marks the company's largest acquisition of the Solana-based coin to date.

Sat, 25/10/2025 - 13:27

Dogecoin has restored confidence to the market as its price shows signs of a major rebound, this has seen short traders go mute in its last hour liquidation.

Cover image via U.Today

Over the past hour, Dogecoin has seen a mild liquidation trend with an unusual twist that suggests bear traders are exiting the market.

According to data provided by CoinGlass, the sudden crypto market resurgence witnessed in the last day has spurred unusual activity in Dogecoin’s derivatives market as a total of $179,110 in liquidations has been recorded in the last hour, with short traders bearing none of it.

DOGE sees $0 liquidation twistAmid the sudden market resurgence, Dogecoin has witnessed extreme abnormalities in its liquidation events, sparking the attention of investors.

HOT Stories

Notably, Dogecoin has registered an unusual one-sided liquidation that saw $179,110 in longs being liquidated over the last hour. This happened to be the only liquidation carried out during the period, as no liquidation was recorded for short traders.

While an abnormal liquidation like this is not commonly witnessed in the Dogecoin derivatives market, the zero activity from DOGE short traders has sparked curiosity among market participants.

It is important to note that, in situations when short traders face little to no liquidations, the basic interpretation is that they have won their bearish bets over the negative movements in the price of the asset at the time.

However, this is not the case this time as Dogecoin has maintained an upward trend in the last 24 hours. This means that no bearish bet could have won during the period.

While DOGE's price was seen moving slowly yet upward during the period, showing signs of a potential rebound, it appears that traders are not certain about a potential downturn in the price of the asset. As such, no short positions were opened during the period.

While Dogecoin is seeing heightened demand as the impressive performance of the first Dogecoin ETF is also seen driving a new wave of fresh momentum for the asset, it is unlikely for traders to be bearish on the asset at a time like this.

Related articles

Why Trust CoinGape

CoinGape has covered the cryptocurrency industry since 2017, aiming to provide informative insights to our readers. Our journal analysts bring years of experience in market analysis and blockchain technology to ensure factual accuracy and balanced reporting. By following our Editorial Policy, our writers verify every source, fact-check each story, rely on reputable sources, and attribute quotes and media correctly. We also follow a rigorous Review Methodology when evaluating exchanges and tools. From emerging blockchain projects and coin launches to industry events and technical developments, we cover all facets of the digital asset space with unwavering commitment to timely, relevant information.

The Ethereum price remains steady near the $3,900 level after multiple failed attempts to reclaim $4,000. The ETH price has shown resilience but faces renewed uncertainty following recent analyst insights. Market participants are closely assessing whether a retest of the $3,800 support zone could trigger a reversal. The outlook remains divided between short-term weakness and optimism surrounding a long-term Ethereum price outlook.

Ethereum price analysis suggests short-term dip could set up a $10K breakout
The Ethereum price remains steady near $3,900 after failing to sustain above $4,000. According to Ted Pillows, ETH might revisit the $3,800 region before any reversal, identifying it as a strong support zone. 

Notably, his chart outlined multiple potential recovery paths, showing that Ethereum could consolidate briefly before reclaiming higher levels. The ETH price has previously respected this zone, reinforcing its structural significance. 

Meanwhile, Ted’s short-term view aligns with a broader belief that the market is pausing before an expansion phase. This perspective ties closely with the 2025 Ethereum price forecast, which continues to project significant upside despite short-term retracements.

ETH/USDT 1-Day Chart (Source: X)
On the other hand, Ali Martinez envisions Ethereum climbing toward the $10,000 mark over the coming years, though not immediately. His long-term chart outlined a steady ascending trendline that could guide the ETH price toward that level by 2027. 

He believes that the $4,250 breakout remains a pivotal confirmation point for Ethereum’s next bullish phase. Additionally, Arthur Hayes echoed similar optimism during his recent Bankless podcast appearance. Hayes reaffirmed his belief that Ethereum remains far from its cycle peak, maintaining his $10,000 target. 

He dismissed current market fluctuations as mere “background noise” within a broader bullish uptrend. Together, both analysts imply that Ethereum’s long-term strength lies in patience, accumulation, and steady conviction.

ETH/USD 1-Week Chart (Source: X)
Around $93M ETF Outflows and BlackRock Dump Weigh on Market Sentiment
Ethereum ETF outflows reached approximately $93 million, marking a notable reduction in institutional exposure. BlackRock alone offloaded $101 million worth of ETH, signaling reduced short-term confidence among large investors.

The massive outflows occurred as Ethereum struggled to stay above the $3,900 mark. Notably, such ETF outflows typically signal bearish sentiment, as institutions exit during consolidation phases.

Meanwhile, the broader derivatives market has yet to show renewed buying pressure. The combined impact of ETF redemptions and corporate sell-offs has slightly weakened investor morale.

However, Ethereum’s strong on-chain fundamentals could eventually offset this short-term caution. Therefore, attention now turns to whether the support near $3,800 can absorb renewed selling pressure.

Summary 
The Ethereum price remains at a critical juncture, balancing between near-term weakness and structural optimism. Analysts believe that a retest of $3,800 could form a base for the next rally. BlackRock’s large-scale sell-off and ETF outflows have added caution, but long-term confidence persists. Therefore, ETH could still position itself for recovery if it successfully defends key support levels.

Following the US Bureau of Labor Statistics’ (BLS) release of its Consumer Price Index (CPI) report, which revealed that inflation rose slightly in September, the crypto market responded with a rise in Bitcoin’s (BTC) price.

This caused a twist in the search for the best crypto to buy today, with ripple effects on other altcoins. Investors’ attention has now shifted to others, such as Chainlink, Cardano, and Remittix (RTX).

These three projects have unique value, but analysts say only one could realistically deliver the massive returns investors seek before year-end.

Bitcoin Price Prospect According to the US CPI Data
The US CPI for September 2025 came in at 3%, which is slightly below the expected 3.1% year-on-year. The Bitcoin price had been experiencing volatility following the October doomsday. Now, it has surged after the release of the new inflation data, with prices rising to $112,194 before stabilizing at $111,474 at the time of writing.

Source: TradingView

Chainlink Growing Adoption and Prospect

Source: TradingView

Chainlink (LINK) network’s thriving crypto staking program has also attracted passive-income seekers, making it one of the best long-term crypto investments in the large-cap crypto market.

However, with Chainlink’s size, massive short-term growth seems doubtful. Analysts predict a 2x-3x gain in Q4 is realistic. That is not the explosive returns investors need. The big breakout they need may lie elsewhere.

How High Can Cardano Rise in 2025?
The ADA price, the network’s stability, and low energy usage make it appealing to long-term investors. Regardless, the token’s growth may remain gradual as analysts note that Cardano is an undervalued crypto project.

Analysts say to expect slow organic growth rather than a breakout. That’s why some ADA holders are diversifying into newer, more promising crypto projects, such as Remittix (RTX).

Remittix is The PayFi Token Experts’ Tip for Consistent and Significant Growth

Remittix (RTX) has built something real, unlike many early-stage projects that overpromise and underdeliver. Here is a cross-chain DeFi project designed for global payments, making sure users can send crypto directly to bank accounts in over 30 countries with low gas fees and transactions settle instantly.

Remittix is connecting blockchain and banking with a real product that works with the following highlights:

$27.7 million raised and 40,000+ holders
Wallet beta live, processing real payments
Ranked #1 on CertiK Skynet for verified project security
15% USDT referral rewards, paid daily
Confirmed listings on BitMart and LBank
Ongoing $250,000 Remittix Giveaway

By combining real utility, early stage pricing, and expanding ecosystem, Remittix is a strong contender among new altcoins to watch in 2025 alongside Cardano, Chainlink and Bitcoin.

Discover the future of PayFi with Remittix by checking out their project here:

Website: https://remittix.io/

Socials: https://linktr.ee/remittix

$250,000 Giveaway: https://gleam.io/competitions/nz84L-250000-remittix-giveaway

This article contains information about a cryptocurrency presale. Crypto Economy is not associated with the project. As with any initiative within the crypto ecosystem, we encourage users to do their own research before participating, carefully considering both the potential and the risks involved. This content is for informational purposes only and does not constitute investment advice.